Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05118776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05118776 · ClinicalTrials.gov record · last posted 2024-10-31

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

StatusActive, Not Recruiting
PhasePhase 3
Started2022-01-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 31, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.

Amendment record 9 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 9 times since 2021-11-02; most recent amendment 2024-10-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-10-30
Status change Recruiting→Active, Not Recruitingv9
2022-01-24
Status change Not Yet Recruiting→Recruitingv4
2021-12-30
Status change Recruiting→Not Yet Recruitingv3
2021-12-01
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05118776
Lead Sponsor Ascletis Pharmaceuticals Co., Ltd.
Conditions Recurrent Glioblastoma
Enrollment 136 participants
Start Date 2022-01-21
Primary Completion 2025-06 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2024-10-31